Cite
HARVARD Citation
Veeraraghavan, J. et al. (2019). A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Annals of oncology. pp. 927-933. [Online].